SCHEMBL2706434

SCHEMBL2706434

c1cc2ncc3cc[nH]c3n2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 4/20 0.36
DYRK1A Q13627 4/20 0.34
DYRK3 O43781 3/20 0.34
CCNT1 O60563 3/20 0.34
CDK9 P50750 3/20 0.34
CDK5 Q00535 3/20 0.34
CDK5R1 Q15078 3/20 0.34
DYRK2 Q92630 3/20 0.34
DYRK1B Q9Y463 3/20 0.34
CCNA2 P20248 2/20 0.34
CDK2 P24941 2/20 0.34
KDR P35968 2/20 0.33
PDE10A Q9Y233 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
AXL P30530 1/20 0.32
NUDT1 P36639 1/20 0.32
PIK3CD O00329 1/20 0.30
PIK3CA P42336 1/20 0.30
PIK3CB P42338 1/20 0.30
PIK3CG P48736 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6207073 0.98 DGAT1 (0.36) DGAT1DYRK1ADYRK3CCNT1CDK9
SCHEMBL1074481 0.75 DGAT1 (0.36) DGAT1DYRK1ACDK2KDRPDE10A
SCHEMBL1647688 0.75 SMN1; SMN2 (0.37) AXLNUDT1MAPK1
SCHEMBL22283892 0.67 DYRK1A (0.39) DGAT1DYRK1AKDRPDE10AMKNK1
SCHEMBL1074480 0.67 DGAT1 (0.36) DGAT1DYRK1AKDRPDE10AMKNK1
SCHEMBL239135 0.66 KDR (0.40) DGAT1DYRK1ACDK9CDK5DYRK1B
SCHEMBL22283907 0.66 MKNK1 (0.41) DGAT1DYRK1ADYRK3CDK5CDK5R1
SCHEMBL239290 0.64 KDR (0.39) DGAT1KDR
SCHEMBL11421107 0.62 PIK3CA (0.38) DGAT1CCNT1CDK9CCNA2CDK2
SCHEMBL867071 0.60 KDR (0.35) DGAT1KDRPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS PROTHENA BIOSCIENCES INC 2025-02-27 US claimed
CN-118843626-A Heterocyclic compounds as DYRK1A inhibitors 普罗塞纳生物科学有限公司 2024-10-25 CN claimed
EP-4444421-A2 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS Prothena Biosciences Limited (IE) 2024-10-16 EP claimed
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO claimed
EP-0369145-B1 Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidine derivatives and medicines comprising the same POLA CHEM IND INC (JP) 1995-12-27 EP claimed
US-4992442-A Bronchodilator agents POLA CHEMICAL INDUSTRIES INC., JAPAN (JP) 1991-02-12 US claimed
EP-0369145-A2 Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidine derivatives and medicines comprising the same POLA CHEMICAL INDUSTRIES INC., JAPAN (JP) 1990-05-23 EP claimed
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS PROTHENA BIOSCIENCES INC 2025-02-27 US disclosed
CN-118843626-A Heterocyclic compounds as DYRK1A inhibitors 普罗塞纳生物科学有限公司 2024-10-25 CN disclosed
EP-4444421-A2 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS Prothena Biosciences Limited (IE) 2024-10-16 EP disclosed
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO disclosed
EP-2736338-B1 FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS MERCK SHARP & DOHME (US) 2019-01-23 EP disclosed
US-8901142-B2 Fused tricyclic compounds as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2014-12-02 US disclosed
EP-0369145-A3 Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidine derivatives and medicines comprising the same POLA CHEMICAL INDUSTRIES INC., JAPAN (JP) 1991-07-17 EP disclosed
US-4992442-A Bronchodilator agents POLA CHEMICAL INDUSTRIES INC., JAPAN (JP) 1991-02-12 US disclosed
US-4992442-A Bronchodilator agents POLA CHEMICAL INDUSTRIES INC., JAPAN (JP) 1991-02-12 US disclosed
US-4992442-A Bronchodilator agents POLA CHEMICAL INDUSTRIES INC., JAPAN (JP) 1991-02-12 US disclosed
EP-0369145-A2 Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidine derivatives and medicines comprising the same POLA CHEMICAL INDUSTRIES INC., JAPAN (JP) 1990-05-23 EP disclosed
EP-0369145-A2 Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidine derivatives and medicines comprising the same POLA CHEMICAL INDUSTRIES INC., JAPAN (JP) 1990-05-23 EP disclosed
EP-0369145-A2 Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidine derivatives and medicines comprising the same POLA CHEMICAL INDUSTRIES INC., JAPAN (JP) 1990-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS DYRK1A, DYRK2, DYRK1B DGAT1 2034/4885DYRK1A 1/4885DYRK3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.